Biomarin Pharmaceutical (BMRN) Acquisitions (2009 - 2016)
Biomarin Pharmaceutical's (BMRN) quarterly Acquisitions came in at $1.3 million in Q4 2016, down 99.75% on a QoQ basis from $538.4 million in Q1 2015.
Analysis
Biomarin Pharmaceutical (BMRN) Acquisitions (2009 - 2016) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 5 years of Acquisitions data on file, last reported at $1.3 million in Q4 2016.
- Quarterly Acquisitions changed N/A year-over-year to $1.3 million in Q4 2016, while the trailing twelve-month figure through Dec 2017 was $1.3 million (changed 0.0% YoY) and the FY2016 annual result came in at $2.8 million, down 99.48% from the prior year.
- Acquisitions declined to $1.3 million in Q4 2016, from $538.4 million in the prior quarter.
- In the past five years, Acquisitions ranged from a high of $538.4 million in Q1 2015 to a low of $1.3 million in Q4 2016.
- A 3-year average of $183.2 million and a median of $9.9 million in 2013 frame the typical range for Acquisitions.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Biomarin Pharmaceutical | 12.88 Bn | 12.01 Bn | 786.91 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2016 | 1.32 Mn |
| Mar 31, 2015 | 538.39 Mn |
| Mar 31, 2013 | 9.88 Mn |
| Sep 30, 2010 | 18.83 Mn |
| Mar 31, 2010 | 14.12 Mn |
| Dec 31, 2009 | 17.52 Mn |